MedTrace Logo

Haloperidol for Delirium in Adult Critically Ill Patients

NCT03628391 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2022-05-11

No results posted yet for this study

Summary

The EuRIDICE trial will study whether haloperidol as a first line treatment for ICU delirium reduces delirium duration (and severity). Adverse outcomes typically associated with delirium will also be studied and include long term cognition, functional outcome and quality of life. Further, patient and family experiences and cost-effectiveness will be assessed. Finally, safety concerns associated with the use of haloperidol in this vulnerable population will be studied.

Conditions

Interventions

DRUG

Haloperidol

haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis

DRUG

Placebo

placebo for ICU delirium, titrated on validated screening tool-based diagnosis

Sponsors & Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Mathieu van der Jagt, MD PhD · Erasmus University Medical Center Rotterdam, The Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-22
Primary Completion
2020-02-03
Completion
2021-01-23

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628391 on ClinicalTrials.gov